Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.
Industry, Sector and Symbol
Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Phone520-365-3100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.67 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable
Accelerate Diagnostics (NASDAQ:AXDX) Frequently Asked Questions
What is Accelerate Diagnostics' stock symbol?
Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."
How were Accelerate Diagnostics' earnings last quarter?
Accelerate Diagnostics Inc (NASDAQ:AXDX) posted its quarterly earnings results on Tuesday, February, 19th. The medical research company reported ($0.41) EPS for the quarter, hitting the consensus estimate of ($0.41). The medical research company had revenue of $1.80 million for the quarter, compared to the consensus estimate of $1.83 million. Accelerate Diagnostics had a negative net margin of 1,564.01% and a negative return on equity of 105.12%. View Accelerate Diagnostics' Earnings History.
When is Accelerate Diagnostics' next earnings date?
What guidance has Accelerate Diagnostics issued on next quarter's earnings?
Accelerate Diagnostics updated its FY 2018 earnings guidance on Monday, January, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $5.7-5.7 million, compared to the consensus revenue estimate of $6.63 million.Accelerate Diagnostics also updated its Q4 2018 guidance to EPS.
What price target have analysts set for AXDX?
3 equities research analysts have issued twelve-month price targets for Accelerate Diagnostics' stock. Their predictions range from $16.00 to $25.00. On average, they anticipate Accelerate Diagnostics' share price to reach $21.00 in the next twelve months. This suggests a possible upside of 2.2% from the stock's current price. View Analyst Price Targets for Accelerate Diagnostics.
What is the consensus analysts' recommendation for Accelerate Diagnostics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Accelerate Diagnostics.
Has Accelerate Diagnostics been receiving favorable news coverage?
Media headlines about AXDX stock have been trending neutral on Friday, according to InfoTrie. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Accelerate Diagnostics earned a news impact score of 0.2 on InfoTrie's scale. They also assigned headlines about the medical research company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
Who are some of Accelerate Diagnostics' key competitors?
Some companies that are related to Accelerate Diagnostics include Coherent (COHR), Horiba (HRIBF), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Quanterix (QTRX), Eyepoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO), Arrayit (ARYC), HTG Molecular Diagnostics (HTGM), BioNano Genomics (BNGO), Aethlon Medical (AEMD), Scientific Industries (SCND), Pressure Biosciences (PBIO), Precipio (PRPO) and PositiveID (PSID).
What other stocks do shareholders of Accelerate Diagnostics own?
Who are Accelerate Diagnostics' key executives?
Accelerate Diagnostics' management team includes the folowing people:
- Mr. Lawrence Mehren, Pres, CEO, Director and Interim Head of Europe, Middle East & Africa (Age 53)
- Mr. Steve Reichling, Chief Financial Officer (Age 41)
- Mr. Ron Price, Sr. VP & Head of Commercial Operations - Americas (Age 55)
- Mr. Kurt Reinhardt, Head of Operations
- Dr. Romney M. Humphries, Chief Scientific Officer
Who are Accelerate Diagnostics' major shareholders?
Accelerate Diagnostics' stock is owned by many different of retail and institutional investors. Top institutional investors include Amundi Pioneer Asset Management Inc. (1.83%), FMR LLC (1.36%), Stifel Financial Corp (1.03%), Artal Group S.A. (0.92%), Nuveen Asset Management LLC (0.82%) and Griffin Asset Management Inc. (0.81%). Company insiders that own Accelerate Diagnostics stock include Jack W Schuler, John Patience, Lawrence Mehren, Steven Reichling and Thomas D Brown. View Institutional Ownership Trends for Accelerate Diagnostics.
Which major investors are selling Accelerate Diagnostics stock?
AXDX stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., Nuveen Asset Management LLC, D. E. Shaw & Co. Inc., Natixis Advisors L.P., Obermeyer Wood Investment Counsel Lllp, Albion Financial Group UT, CIBC Private Wealth Group LLC and Northern Trust Corp. View Insider Buying and Selling for Accelerate Diagnostics.
Which major investors are buying Accelerate Diagnostics stock?
AXDX stock was acquired by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Raging Capital Management LLC, Griffin Asset Management Inc., FMR LLC, Stifel Financial Corp, Intrinsic Edge Capital Management LLC, RMB Capital Management LLC and First Trust Advisors LP. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Jack W Schuler, John Patience, Steven Reichling and Thomas D Brown. View Insider Buying and Selling for Accelerate Diagnostics.
How do I buy shares of Accelerate Diagnostics?
Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Accelerate Diagnostics' stock price today?
One share of AXDX stock can currently be purchased for approximately $20.54.
How big of a company is Accelerate Diagnostics?
Accelerate Diagnostics has a market capitalization of $1.12 billion and generates $5.67 million in revenue each year. The medical research company earns $-88,330,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis.
What is Accelerate Diagnostics' official website?
How can I contact Accelerate Diagnostics?
Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at 520-365-3100 or via email at [email protected]
MarketBeat Community Rating for Accelerate Diagnostics (NASDAQ AXDX)
MarketBeat's community ratings are surveys of what our community members think about Accelerate Diagnostics and other stocks. Vote "Outperform" if you believe AXDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
